AJOVista LLC Makes New Investment in MacroGenics, Inc. (NASDAQ:MGNX)

AJOVista LLC bought a new position in shares of MacroGenics, Inc. (NASDAQ:MGNX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,344 shares of the biopharmaceutical company’s stock, valued at approximately $51,000.

Other large investors also recently modified their holdings of the company. GSA Capital Partners LLP lifted its holdings in MacroGenics by 74.9% in the third quarter. GSA Capital Partners LLP now owns 225,918 shares of the biopharmaceutical company’s stock worth $1,053,000 after acquiring an additional 96,760 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of MacroGenics during the 3rd quarter worth approximately $281,000. Silverarc Capital Management LLC lifted its holdings in shares of MacroGenics by 4.0% in the 3rd quarter. Silverarc Capital Management LLC now owns 1,264,158 shares of the biopharmaceutical company’s stock worth $5,891,000 after purchasing an additional 48,483 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in MacroGenics by 32.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 194,204 shares of the biopharmaceutical company’s stock valued at $905,000 after purchasing an additional 48,118 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in MacroGenics during the 3rd quarter worth $649,000. 96.89% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on MGNX. B. Riley began coverage on MacroGenics in a research note on Friday, April 26th. They issued a “buy” rating and a $25.00 target price on the stock. HC Wainwright lowered shares of MacroGenics from a “buy” rating to a “neutral” rating and boosted their target price for the company from $12.00 to $14.00 in a research note on Wednesday, February 14th. Barclays raised their price target on shares of MacroGenics from $12.00 to $23.00 and gave the company an “overweight” rating in a research note on Thursday, February 29th. TheStreet downgraded MacroGenics from a “c” rating to a “d” rating in a research report on Thursday, March 7th. Finally, BTIG Research increased their price objective on MacroGenics from $12.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, March 4th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Insider Activity at MacroGenics

In other MacroGenics news, VP Jeffrey Stuart Peters sold 51,395 shares of the company’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $15.55, for a total value of $799,192.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 11.30% of the company’s stock.

MacroGenics Trading Up 3.0 %

MacroGenics stock opened at $15.67 on Monday. MacroGenics, Inc. has a 12-month low of $4.29 and a 12-month high of $21.88. The firm has a 50 day simple moving average of $16.46 and a 200-day simple moving average of $12.43.

MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.49). MacroGenics had a negative net margin of 15.42% and a negative return on equity of 88.49%. The firm had revenue of $10.72 million for the quarter, compared to the consensus estimate of $25.70 million. During the same period in the previous year, the business posted $0.21 earnings per share. As a group, equities analysts predict that MacroGenics, Inc. will post -2.7 EPS for the current year.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.